Corteva (CTVA) AI Stock Analysis

Compare

1,717 Followers

Top Page

Corteva

(NYSE:CTVA)

Select Model

Outperform 71 (OpenAI - 5.2)

Rating:71Outperform

Price Target:

$83.00

▲(8.77% Upside)

Action:ReiteratedDate:02/05/26

The score is driven primarily by solid financial health (low leverage, improving margins, strong recent free cash flow) and a constructive earnings outlook with reiterated 2026 growth guidance and licensing/royalty tailwinds from the Bayer agreement. These positives are tempered by a rich valuation (high P/E, low yield) and technically overbought momentum, plus revenue inconsistency and pricing/tariff/FCF-normalization risks highlighted on the call.

Positive Factors

Conservative Balance Sheet

Low leverage and a sizable equity base provide durable financial flexibility. This supports funding for R&D, separation costs, opportunistic M&A or share repurchases, and cushions the business through commodity or seasonal cycles without forcing rapid deleveraging that could impair operational investment.

Strong Free Cash Flow Generation

Consistent, high free cash flow versus reported earnings indicates strong cash conversion and earnings quality. Durable FCF enables sustained dividends, buybacks and reinvestment in the seed and crop-protection pipeline, making the company less reliant on external capital across multi-year cycles.

Bayer Agreement and Licensing Upside

The comprehensive Bayer settlement is a structural positive: it reduces royalty risk, accelerates commercialization timelines and broadens licensing opportunities. That creates a multi-year earnings tailwind and speeds deployment of next-gen platforms, strengthening long-term revenue and margin prospects.

Negative Factors

Inconsistent Revenue Trends

Declining or stagnant top-line growth weakens earnings durability: margin gains and productivity can offset but not fully substitute consistent revenue expansion. A shrinking or inconsistent revenue base increases reliance on one-time productivity gains and licensing to sustain long-term profit growth.

Crop Protection Pricing Pressure

Sustained competitive pricing and generics pressure in key CP markets like Brazil can erode margins structurally. Given CP's contribution to earnings, persistent price declines could offset productivity gains and force higher investment in differentiation or mix-shifting to recover long-term profitability.

FCF Volatility & Separation Timing

Cash flow tied to working-capital swings and one-off separation costs creates durable uncertainty in free cash availability. Reduced FCF conversion and near-term separation cash needs limit flexibility for returns or investment, and increase execution risk around planned repurchases and separation-related objectives.

Corteva (CTVA) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$51.51B

Dividend Yield1.04%

Average Volume (3M)3.99M

Price to Earnings (P/E)47.7

Beta (1Y)0.59

Revenue Growth5.00%

EPS Growth136.31%

CountryUS

Employees22,000

SectorBasic Materials

Sector Strength58

IndustryAgricultural Inputs

Share Statistics

EPS (TTM)0.22

Shares Outstanding672,524,000

10 Day Avg. Volume3,710,459

30 Day Avg. Volume3,985,762

Financial Highlights & Ratios

PEG Ratio1.80

Price to Book (P/B)1.87

Price to Sales (P/S)2.59

P/FCF Ratio16.03

Enterprise Value/Market Cap0.96

Enterprise Value/Revenue2.84

Enterprise Value/Gross Profit6.13

Enterprise Value/Ebitda16.11

Forecast

1Y Price Target

$84.55

Price Target Upside10.80% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering13

EPS Forecast (FY)3.63

Revenue Forecast (FY)$18.09B

Corteva Business Overview & Revenue Model

Company DescriptionCorteva, Inc. operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability. The Crop Protection segment offers products that protect against weeds, insects and other pests, and diseases, as well as enhances crop health above and below ground through nitrogen management and seed-applied technologies. This segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management herbicides. It serves agricultural input industry. The company operates in the United States, Canada, Latin America, the Asia Pacific, Europe, the Middle East, and Africa. Corteva, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana.

How the Company Makes MoneyCorteva generates revenue primarily through the sale of its seeds and crop protection products to farmers and agricultural retailers worldwide. The Seed segment is a significant revenue driver, as it includes both genetically modified and traditional seed varieties, which are sold at a premium price due to their yield-enhancing traits. The Crop Protection segment contributes to earnings by providing essential chemicals that protect crops from pests and diseases, thus ensuring higher yields for farmers. Additionally, Corteva engages in strategic partnerships with various agricultural stakeholders, including research institutions and technology companies, to enhance its product offerings and expand its market reach. The company's innovation in agricultural biotechnology and sustainable farming practices also plays a crucial role in attracting customers and driving sales growth.

Corteva Key Performance Indicators (KPIs)

Any

Revenue by Segment

Revenue by Segment
Breaks down total revenue by business segment, offering a clear view of which areas drive growth and contribute most to the company's financial health.

Chart InsightsCorteva's Seed segment shows consistent growth, bolstered by strategic price capture and market share gains in North America, with promising expansion in Brazil. Despite competitive pricing pressures in the Crop Protection segment, earnings and margins are improving, driven by innovation like the new insecticide, Varpelgo. The company's raised financial guidance and robust performance in both segments reflect strong strategic execution, though challenges persist in Latin America's credit markets. Overall, Corteva's focus on innovation and productivity is expected to sustain its growth trajectory.

Data provided by:

The Fly

Corteva Earnings Call Summary

Earnings Call Date:Feb 03, 2026

(Q4-2025)

% Change Since: |

Next Earnings Date:May 06, 2026

Earnings Call Sentiment Positive

The call conveyed a broadly positive outlook driven by strong 2025 results (14% EBITDA growth, margin expansion to >22%, $2.9B FCF), successful strategic progress (Bayer settlement accelerating licensing and reducing royalty risk), and reiterated 2026 guidance with continued productivity targets. Key near-term risks include Q4 timing-related volume softness, competitive pricing pressures in Crop Protection (notably Brazil), currency headwinds in 2025 and expected tariff impacts in 2026, along with higher SG&A/R&D and potential normalization of working capital that could temper free cash flow. On balance, the company highlighted more material progress and upside catalysts than offsets, with a clear path to additional licensing revenue and margin/cash improvement.

Q4-2025 Updates

Positive Updates

Strong Full-Year Financial Performance

Full-year 2025 operating EBITDA of $3.85 billion, up roughly $470 million (about +14% year-over-year), with operating EBITDA margin expanding over ~215 basis points to above 22%.

Revenue and Organic Sales Growth

Full-year organic sales grew ~4% versus prior year; second-half sales up 4% with operating EBITDA up 16% in H2 driven by better price/mix in Seed and volume gains across both segments.

Record Free Cash Flow and Capital Returns

Free cash flow improved by about $1.2 billion to $2.9 billion in 2025; returned approximately $1.5 billion to shareholders in fiscal 2025 via dividends and share repurchases and targeting ~$500 million of share repurchases in 1H 2026.

Seed Business Momentum and Cost/Royalty Improvements

Seed delivered organic growth in every region, share gains in corn and soy, ~$340 million of net cost improvements and ~$90 million of royalty improvement in 2025; net royalty expense ended the year around $120 million.

Crop Protection Growth and Innovation Pipeline

Crop Protection delivered top-line and bottom-line growth in 2025, volume up ~5% for the year, biologicals produced double-digit volume gains, and the business has a $9 billion pipeline of differentiated technologies; CP delivered over $300 million of productivity/cost benefits for the full year.

Bayer Agreement Accelerates Licensing and Reduces Royalty Risk

Comprehensive resolution with Bayer completed, ~$610 million payment mostly completed; expect royalty neutrality in 2026 (2 years ahead of prior plan), acceleration of corn licensing to as early as 2027 (accelerated ~5 years), earlier introduction of third-gen platforms (~2 years earlier) and entry into U.S. cotton licensing; agreement expected to generate ~ $1 billion aggregate earnings upside over the next 10 years.

2026 Guidance Reiterated with Growth

2026 operating EBITDA guidance range $4.0–$4.2 billion with midpoint $4.1 billion (~+7% vs. 2025 midpoint); operating EPS guide $3.45–$3.70 (about +7% at midpoint); ~ $120 million improvement in net royalty expense, ~$200 million productivity savings, and a currency tailwind expected to add ~ $75 million to EBITDA.

Separation Progress and Capital Structure Planning

Separation remains on track for second half (likely Q4) 2026 with plans for Form 10 filings, management team announcements, Board appointments and IT separation; estimated net dissynergies roughly $100 million with ~$50 million built into 2026 guide.

Negative Updates

Q4 Near-Term Weakness and Volume Timing Shifts

Q4 2025 sales and operating EBITDA were down versus prior year; Q4 organic sales down ~4%. Seed volumes declined ~8% in Q4 (timing shifts such as safrinha sales and North America deliveries moved into 1H 2026); CP volumes down ~2% in Q4 due to seasonal/timing shifts.

Crop Protection Pricing Pressure

Crop Protection price was down ~2% for the full year and management expects low single-digit price declines in CP in 2026 due to competitive pricing dynamics, especially in Latin America and parts of Asia-Pacific.

SG&A and R&D Expense Increases

SG&A and R&D increased in 2025: Q4 SG&A rose from $735 million to $860 million (approximately +$125 million) and R&D increased ~ $50 million; full-year SG&A up driven by higher commissions and compensation.

Currency Headwinds in 2025

Currency translation was a ~$217 million headwind on EBITDA in 2025, driven primarily by weakness in the Brazilian real, Canadian dollar and Turkish lira.

Tariff and Trade-Related Costs

Management expects approximately $80 million of tariff-related headwinds in 2026 (primarily impacting Crop Protection, largely tied to China imports into the U.S.).

Free Cash Flow Normalization and One-Off Impacts

Portion of the strong 2025 free cash flow was driven by unusually favorable working capital positions and favorable cash-credit mix; normalization of working capital is expected to reduce FCF conversion in 2026. Additionally, FCF in 2026 will be impacted by separation-related items and the Bayer agreement payment timing.

Channel and Competitive Dynamics in Brazil

Brazil Crop Protection saw heavy generics competition and pricing pressure; ample supply and import dynamics created margin pressure in that market and contributed materially to CP price declines in 2025.

Concentration of Earnings Timing

Management expects ~60% of 2026 sales but roughly 85% of 2026 EBITDA to be delivered in the first half of the year, indicating concentrated timing risk if seasonality or demand patterns shift.

Company Guidance

Corteva reiterated 2026 guidance of operating EBITDA $4.0–$4.2 billion (midpoint $4.1B, ~7% growth vs. 2025’s $3.85B), operating EPS $3.45–$3.70 (≈7% increase at midpoint), and roughly 50 basis points of margin expansion; the plan assumes about $120M of net royalty improvement, ~$200M of productivity savings, an ~$80M tariff headwind, and ~$50M of net dissynergies already built in, with currency providing roughly a $75M EBITDA tailwind (low-single-digit sales tailwind); they expect Seed pricing slightly up and volumes roughly flat, Crop Protection volumes up mid-single digits but prices down low-single digits, about 60% of 2026 sales and ~85% of EBITDA to occur in H1, FCF to be impacted by separation items and the Bayer payment (the $610M cash payment recently made) yet the company is targeting ~$500M of share repurchases in H1 and remains committed to returning cash to shareholders.

Corteva Financial Statement Overview

Summary

Strong financial foundation with low leverage and improved profitability and cash generation (2025 FCF ~$2.9B). The key offset is inconsistent/declining revenue in recent years, which raises durability risk despite margin gains.

Income Statement

Positive

Profitability improved meaningfully over the last two years, with gross margin rising from ~40% (2022) to ~46% (2025) and operating margin expanding to ~14% (2025). Net margin also recovered to ~6.3% (2025) from ~4.3% (2023). The key offset is top-line momentum: revenue has been flat-to-down recently (negative growth in 2023–2025, including a sharp drop in 2025), which limits overall earnings durability despite better margins.

Balance Sheet

Very Positive

The balance sheet is conservatively positioned with low leverage: debt-to-equity remains around ~0.10 (2025) and has been consistently modest across the period. Equity is sizable and stable, supporting financial flexibility. Returns are adequate but not strong—return on equity is in the mid-single digits (~4–5% in 2024–2025), suggesting the company is not currently generating high profitability relative to its capital base.

Cash Flow

Positive

Cash generation is a clear strength: operating cash flow and free cash flow are both solid and improved in 2024–2025, with free cash flow reaching ~$2.9B in 2025. Free cash flow has also consistently represented a large portion of net income (roughly ~66% to ~83% over 2023–2025), indicating good earnings quality. The main caution is volatility earlier in the period (notably weak 2022 free cash flow), implying cash conversion can swing with working capital and cycle dynamics.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	17.40B	16.91B	17.23B	17.45B	15.65B
Gross Profit	7.58B	7.38B	7.31B	7.02B	6.43B
EBITDA	3.07B	2.73B	2.54B	2.73B	3.62B
Net Income	1.09B	907.00M	735.00M	1.15B	1.76B
Balance Sheet
Total Assets	42.84B	40.83B	43.00B	42.62B	42.34B
Cash, Cash Equivalents and Short-Term Investments	4.53B	3.17B	2.74B	3.31B	4.54B
Total Debt	2.58B	2.70B	2.49B	1.31B	1.12B
Total Liabilities	18.46B	16.80B	17.72B	17.08B	16.72B
Stockholders Equity	24.14B	23.79B	25.04B	25.30B	25.38B
Cash Flow
Free Cash Flow	2.81B	1.55B	1.17B	267.00M	2.15B
Operating Cash Flow	3.41B	2.15B	1.77B	872.00M	2.73B
Investing Cash Flow	-543.00M	-589.00M	-1.99B	-632.00M	-362.00M
Financing Cash Flow	-1.64B	-1.20B	-99.00M	-1.18B	-1.27B

Corteva Technical Analysis

Technical Analysis Sentiment

Positive

Last Price76.31

Price Trends

50DMA

70.40

Positive

100DMA

67.21

Positive

200DMA

69.35

Positive

Market Momentum

MACD

1.68

Negative

RSI

64.46

Neutral

STOCH

94.18

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTVA, the sentiment is Positive. The current price of 76.31 is above the 20-day moving average (MA) of 74.16, above the 50-day MA of 70.40, and above the 200-day MA of 69.35, indicating a bullish trend. The MACD of 1.68 indicates Negative momentum. The RSI at 64.46 is Neutral, neither overbought nor oversold. The STOCH value of 94.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTVA.

Corteva Risk Analysis

Corteva disclosed 31 risk factors in its most recent earnings report. Corteva reported the most risks in the "Legal & Regulatory" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Corteva Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CF	79 Outperform	$14.95B	10.68	29.62%	2.56%	12.59%	31.40%
CTVA	71 Outperform	$51.51B	47.70	4.98%	1.04%	5.00%	136.31%
MOS	65 Neutral	$9.34B	7.64	10.00%	3.70%	3.82%	239.39%
SMG	62 Neutral	$4.05B	47.24	―	4.52%	-3.93%	―
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ICL	60 Neutral	$7.10B	31.41	3.86%	3.36%	1.77%	-8.72%
FMC	49 Neutral	$1.81B	-0.83	-66.80%	16.68%	-13.42%	-136.59%

* Basic Materials Sector Average

Performance Comparison

CTVA

Corteva

76.31

14.34

23.14%

Cf Industries Holdings

97.18

21.43

28.29%

FMC

14.62

-21.68

-59.73%

MOS

Mosaic Co

29.43

4.87

19.81%

SMG

Scotts Miracle-Gro Company

69.96

12.46

21.66%

ICL

Icl

5.43

-0.50

-8.43%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 05, 2026